immunology cell hero

Immunology

A trusted leader dedicated to transforming the lives of people with immune-mediated diseases, today and tomorrow.

Raising the standard for all

With each new discovery, we create a better understanding of how people are different - even those diagnosed with the same disease - so we can develop more personalised approaches to immunological diseases.  

Scientists at the AbbVie Bioresearch Center in Massachusetts focus on innovative solutions for some of medicine’s toughest challenges, including immunology.

Research interests

We’re building on our deep expertise and historic legacy in immunology research to explore new disease areas, create a more patient-centric discovery and development process, and offer solutions for more diverse patient populations. Our advanced technologies support a rich pipeline of medicines for some of the most challenging immunological diseases. 

Our research interests include: understanding drivers of disease; redesigning drug discovery to reveal the genetic makeup of disease; increasing the probability of success in drug discovery; inducing immune tolerance; targeted drug delivery platforms. 

 

Topics

Immunology focus areas

We work to help people living with chronic, progressive diseases in rheumatology, dermatology and gastroenterology live full lives with fewer limits from their disease. 


immunology focus areas:

Key Commitments

Innovation strengths  

Across disease areas and development stages, we follow 3 principles to drive innovation forward.  


Partnerships

Strategic collaborations bring together the brightest minds in immunology working to bring more options to patients, faster. We join forces with partners that complement our strengths, capabilities and commitment to people with immune-mediated diseases. 



Precision medicine

Innovation in this area helps researchers understand complex immune-mediated diseases, from how a person’s genetics affect disease to leveraging clinical trial data to deliver personalised medicine. Advanced technologies like molecular profiling and biomarker analyses allow us to dig even deeper.  



Portfolio mindset

Portfolio mindset: We have nearly a quarter-century of experience in immune-mediated disease, and we’re not stopping. We continue to investigate diseases with critical unmet needs, building robust development programmes that advance how the disease is treated.


UK-ABBV-260029 | February 2026